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Abstract
Background: Inflammatory activation plays a vital role in the pathophysiological mechanisms of stroke, exerting
deleterious effects on the progression of tissue damage and may lead to the vascular damage in diabetes. The
objectives of this study were to determine the effects of rosmarinic acid (RA) on a cultured neuronal cell line, SH-SY5Y
in vitro and experimental ischemic diabetic stroke in vivo.
Methods: For oxygen-glucose deprivation (OGD) and tumor necrosis factor-α (TNF-α) stimulated SH-SY5Y cell line
in vitro, SH-SY5Y cells were incubated with RA. For an in vivo experiment, diabetic rats were subjected to middle
cerebral artery occlusion (MACO) for 40 minutes followed by reperfusion for 23 h.
Results: Treatment of SH-SY5Y cells with RA reduced the OGD-induced apoptosis and cytotoxicity, blocked
TNF-α-induced nuclear transcription factor κB (NF-κB) activation, and decreased high-mobility group box1 (HMGB1)
expression. At doses higher than 50 mg/kg, RA produced a significant neuroprotective potential in rats with ischemia
and reperfusion (I/R). RA (50 mg/kg) demonstrated significant neuroprotective activity even after delayed
administration at 1 h, 3 h and 5 h after I/R. RA 50 mg/kg attenuated histopathological damage, decreased brain edema,
inhibited NF-κB activation and reduced HMGB1 expression.
Conclusion: These data show that RA protects the brain against I/R injury with a favorable therapeutic time-window
by alleviating diabetic cerebral I/R injury and attenuating blood–brain barrier (BBB) breakdown, and its protective
effects may involve HMGB1 and the NF-κB signaling pathway.
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Background
Ischemic stroke is a leading cause of death and disability,
resulting from a transient or permanent reduction in
cerebral blood flow in a major brain artery. Each year
750,000 strokes occur in the US. A large number of
survivors experience permanent neurological damage,
which impacts the quality of life. The annual cost for the
treatment of stroke victims is over 50 billion dollars per
year. In spite of substantial research and development
efforts, no sufficiently effective therapy for this obstinate
illness is available.
Diabetes mellitus (DM) is associated with both micro-
vascular and macrovascular diseases affecting several
organs. Consequently, DM not only increases the risk of is-
chemic stroke but also increases recurrence of stroke and
poorer outcomes after stroke [1,2]. For nearly 20 years, the
number of Chinese diabetes patients has been in a growth
spurt [3]. Therefore, investigation of the neuroprotective
effects of diabetic stroke is warranted in non-streptozotocin
(WT) middle cerebral artery occlusion (MCAO) rats.
The inflammatory response to brain injury, especially
NF-κB activation, plays a vital role in the pathogenesis of
ischemic stroke [4]; inhibition of NF-κB may represent a
treatment strategy in ischemic stroke [5]. High-mobility
group box1 (HMGB1), a nonhistone DNA-binding pro-
tein, has been reported to be massively released into the
extracellular space immediately after an ischemic insult
and to induce neuroinflammation and microglial activa-
tion in the post-ischemic brain [6]. Extracellular HMGB1
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contributes to the pathogenesis of brain disorders. A large
body of information indicates that HMGB1 is involved in
severe inflammatory reactions and plays a significant part
in the progression of ischemic brain injury [7-9]. Thus,
HMGB1 is a key regulator of the neuro-immune system
which is involved in progression of neurologic disorders.
Therefore, inhibition of HMGB1 release may be a novel
therapeutic strategy for treating diabetic cerebral ischemia.
Rosmarinic acid (RA) is a natural, phenol, antioxidant
carboxylic acid. Many bioactivities of RA have been
reported, such as anti-liver fibrosis [10], antisepsis [11]
and anti-diabetic nephropathy [12]. There is no report
which has demonstrated the role of HMGB1 and NF-κB
in the neuroprotective effect of RA on diabetic rats with
cerebral ischemic injury. In the present study, we, therefore,
investigate the hypothesis that RA plays a neuroprotective
role through the abrogation of HMGB1 release and
NF-κB activation triggered by tumor necrosis factor-α
(TNF-α) and ameliorates diabetic rats with MCAO-
induced cerebral ischemia/reperfusion injury.
Methods
Materials
Rosmarinic acid (RA, Molecular Formula: C21H20O10;
CAS NO.: 32769-01-0, purity >98.3%,) was provided by
the State Key Laboratory of Long-acting Extended-
Release and Targeting Drug Delivery System, Yantai, PR
China.
Cell culture
Human neuroblastoma (SH-SY5Y) cells were obtained
from the Shanghai cell bank of the Chinese Academy of
Sciences. SH-SY5Y cells were cultured and maintained
in F12 + DMEM (1:1, v/v) media, supplemented with
10% FBS and 1% penicillin/streptomycin. Cells were kept
at 37°C in a humidified 5% CO2/95% O2 incubator. The
dissociated cells were seeded in poly-L-lysine-coated
plates at a density of 5 × 105/cm2 and cultured in DMEM
(Shanghai lifetechnologies, PR China), supplemented with
10% (v/v) horse serum, 5% (v/v) fetal bovine serum, 100
U/ml penicillin and 0.1 mg/ml streptomycin. The fresh
medium was changed twice weekly. After eight days of
culture, the SH-SY5Y cells were randomly divided into
seven groups: a normal group (no oxygen-glucose
deprivation), an oxygen-glucose deprivation group
(control group) and oxygen-glucose deprivation + RA
groups (1, 3, 9, 27 and 81 μM). RA was dissolved in sa-
line. For oxygen-glucose deprivation, the SH-SY5Y
cells were washed twice in glucose-free balanced salt
solution (BSS) containing 130 mM NaCl, 5.5 mM KCl,
1.8 mM CaCl2, 1.0 mM MgCl2, and 20 mM HEPES
(pH 7.4), and incubated in BSS (no glucose) in a hu-
midified chamber filled with 95% N2/5% CO2 for 3 h at
36.5°C. After oxygen-glucose deprivation, the cultures
were replaced into neurobasal medium and incubated
with RA (1, 3, 9, 27 and 81 μM) in a CO2 incubator
for 12 h.
Determination of cell viability, lactic dehydrogenase
(LDH) leakage and apoptosis
After oxygen-glucose deprivation for 3 h followed by
12 h incubation with or without RA, cell viability was
assessed using a 3-(4, 5)-dimethylthiahiazo (−z-y1)-3,
5-di-phenytetrazoliumromide (MTT) assay. LDH, an
indicator of cell injury, was detected according to the
description of the LDH assay kit (Beijing Zhongsheng
Bioreagent, Beijing, PR China). LDH leakage rate (%) =
Ae/At*100%. Ae indicated extracellular lactic dehydro-
genase (LDH, cells culture fluid), At indicated intracel-
lular and extracellular LDH (cells lysate). Apoptotic
cells were evaluated using an Annexin-V fluorescein
isothiocyanate (FITC) apoptosis detection kit (Haimen
Beyotime Biotechnology Institute, Jiangsu, PR China.
In brief, cells were harvested, washed and incubated at
4°C for 30 minutes in the dark with annexin-V FITC
and propidium iodide, then analyzed on a FACS Vant-
age SE flow cytometer (Beckman Coulter, Fullerton,
CA, USA).
Animals
Adult male Sprague–Dawley rats were obtained from
Shandong Luye Pharmaceutical Company (Yantai, PR
China). All animals were housed individually at 22 ± 2°C
and a relative humidity of 50 ± 10% with a 12-h light/
dark cycle and had free access to chow and water. All
procedures (including rat cerebral ischemia study
protocol) were carried out in accordance with the Na-
tional Institute of Health Guide for the Care and Use
of Laboratory Animals (NIH Publications No. 80–23)
revised 1996.
Streptozotocin (STZ)-induced diabetes animal model and
rat cerebral ischemia study protocol
Two hundred and eighty rats (fasting for 20 h) were
induced by single intraperitoneal injection (i.p.) of STZ
at a dose of 45 mg⁄ kg. STZ was diluted in citrate buffer
0.1 M (pH 4.0). After STZ injection for three weeks, rats
with a glycemia value between 11.0 to 22.0 mM were
used. The diabetic rats were anesthetized with chloral hy-
drate (350 mg/kg, i.p.). Rectal temperature was recorded
and maintained at 37°C throughout the surgical proced-
ure. The operation of MCAO was carried out according
to previous procedures with minor modifications [13].
The adequacy of the anesthesia was monitored by the
level and stability of the mean arterial pressure (MAP)
and absence of corneal reflex, and adequate levels of
anesthesia and analgesia were ensured with supplemental
i.p. injection of pentobarbital sodium given as required.
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The left common carotid artery was occluded, and the
branches of the external carotid artery were dissected and
divided. The internal carotid artery was followed rostrally
and a 4–0 filament (Beijing Shadong Biology Company,
Beijing PR China. A filament (with a diameter of 0.25, and
a tip diameter of 0.34 mm to create a globular stopper)
was introduced into the internal carotid artery and
advanced until resistance was felt. The filament was
removed after 40 minutes. The rats were kept under con-
trol temperature (24°C to 25°C) conditions for the first
24 h after surgery.
For dose–response studies, 70 rats were randomly
divided into seven groups of 10 rats each plus 10 rats as
control (no diabetic). RA at doses of 0, 12.5, 25, 50, 100
or 200 mg/kg was administered by intravenous bolus in-
jection into the tail vein 30 minutes after reperfusion.
Diabetic or vehicle-treated rats were administered with
saline. Rectal temperature was determined once every
3 h for a total of eight times. Neurological deficits were
determined at 24 h after ischemia followed by brain in-
farct volume examination.
For therapeutic time-window studies, 50 rats were ran-
domly divided into five groups of 10 rats each. Rats
received a dose of 50 mg/kg by intravenous bolus injec-
tion into the tail vein 1 h, 3 h, 5 h and 7 h after
reperfusion. Vehicle-treated rats were administered with
saline. Neurological deficits were determined 24 h after
ischemia followed by brain infarct examination.
For anti-inflammatory mechanism studies, 45 rats
were randomly divided into three subgroups of 15 rats
each, plus 15 rats as control (no diabetic). Rats received
doses of 50 mg/kg intravenous bolus injections into the
tail vein 30 minutes after reperfusion. Diabetic or vehicle-
treated rats were administered with saline. The above
three groups were evaluated for Evans blue extravasation,
Western blots analysis, and histopathological damage by
NeuN staining.
For long-term studies, 30 rats were randomly divided
into two groups of 15 rats each. Rats received doses of
50 mg/kg by intravenous bolus injection into the tail
vein 30 minutes after reperfusion. The vehicle-treated
rats were administered with saline. Neurological deficits
were determined at the 3rd, 7th and 14th day after I/R.
Fourteen days after I/R, seven rats in each group were
randomly selected for brain infarct examination according
to a previous method [14].
Evaluation of neurological deficits
Neurological deficits were evaluated using a modified
six-point scoring method [15] by an investigator who
was blinded to each experimental group. The scale is 0,
no neurological deficits (normal); 1, failure to extend left
forepaw fully (mild); 2, circling to the left (moderate); 3,
falling to the left (severe); 4, no spontaneous walking
with a depressed level of consciousness (very severe),
and 5, death.
Evaluation of infarct volume and brain water content
After 23 h of reperfusion, rats were anesthetized with so-
dium pentobarbital (40 mg/kg) through intraperitoneal
injection, and the brain was quickly removed. Total wet
weight of the brain was measured accurately. Brain was
cut at the forebrain 3 mm, and each brain was sliced
into five coronal sections of 2-mm thickness each, then
stained with a 2% solution of tetrazolium chloride (TTC,
Sigma, Shanghai, PR China) in saline at 37°C for 20 -
minutes, and photographed. The images were digitized,
and infarct volume was calculated with a Compix system
computer (C imaging 1280 system, Compix Inc., Cran-
berry. Township, PA, USA). Afterwards, brain water
content was determined as an indicator of cerebral
edema using a wet/dry method.
Evaluation of blood–brain barrier (BBB) leakage with
Evans blue extravasation
Determination of Evans blue extravasation was based on
a previous method [16] with minor modifications. After
reperfusion, 0.1 ml of 4% Evans blue (Urchem, Shanghai,
PR China) in 0.9% saline was intravenously administered.
Twenty-three hours after I/R, rats were anesthetized
with chloral hydrate (350 mg/kg, i.p.), then perfused with
20 ml 10 U/ml heparinized saline to wash out the blood,
the brain was then isolated, weighed and homogenized in
50% solution of trichloroacetic acid. After centrifugation
at 400 × g for 20 minutes, the supernatant was spectro-
photometrically measured at 595 nm. Cerebral Evans blue
was quantified as micrograms of dye per gram of wet
weight.
NF-κB binding assay
SH-SY5Y cells (5 × 106) were pre-incubated with RA
9 μM for 22 h, then incubated with TNF-α (20 ng/ml)
for 1 h or 2 h, then washed once with phosphate-
buffered saline (PBS), scraped cells into 1 mL cold
PBS, and pelleted by centrifugation. Nuclear extracts
were prepared as described previously [17]. The DNA
binding activity of NF-κB (p50/p65) was determi-
ned using an ELISA kit (Solar Biology Technology
Company, Shanghai, PR China).
Western blots analysis
For the experiment of TNF-α stimulated SH-SY5Y cell
lines in vitro, SH-SY5Y cells (5 × 106) were pre-
incubated with RA (9 μM) or HMGB1 inhibitor,
glycyrrhizin (100 μM) for 120 minutes, then incubated
with TNF-α (20 ng/ml) for 30 minutes and cultured
in a CO2 incubator for 12 h. Cells were washed twice with
ice cold PBS on ice and lysed in NP40 lysis buffer
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(Biosource, Camarillo, CA, USA) (50 mM Tris, pH 7.4,
250 mM NaCl, 5 mM EDTA, 50 mM NaF, 1 mM Na3VO4,
1% NP-40 and 0.02% NaN3) supplemented with 1 mM
PMSF and 1 × protease inhibitor cocktail (Sigma, Saint
Louis, MO, USA).
For Western blot analysis of collected brain tissues,
the tissues were defrosted and immersed in ice-cold
NP40 lysis buffer. Equal amounts of cell protein (50 μg)
were separated by SDS-PAGE and analyzed by Western
blot using specific antibodies to HMGB1, IκB, phosphor-
IκB-α, phosphor-NF-κB and proliferating cell nuclear
antigen (PCNA, loading control). All antibodies were
purchased from Beijing Biosynthesis Biotechnology Com-
pany (Beijing, PR China). Optical densities of the bands
were scanned and quantified with a Gel Doc 2000 (Bio-
Rad laboratories, Milan, Italy). Data were normalized
against those of the corresponding PCNA bands. Results
were expressed as fold increase over control or sham
group.
Myeloperoxidase (MPO) activity assay
The remaining slices of the brain, not used for Western
blot analysis, were used to determine MPO activity as
described previously [18]. For each individual rat, the is-
chemic and non-ischemic hemispheres (from the six
slices) were pooled separately for the assay, and wet
weight was then recorded. The tissues were homogenized
(1: 20, wt/vol) in 5 mmol/L phosphate buffer (pH 6, 4°C)
and centrifuged at 30,000 g for 30 minutes (4°C). MPO ac-
tivity was determined according to the kit instructions
(Xitang Biology Technology Company, Shanghai, PR
China). MPO activity for each tissue sample is normalized
on the basis of grams per wet weight of tissue.
NeuN staining
The left hemisphere of the brain was cut coronally into
three blocks from the level of the optic chiasm and the
infundibular stem of the hypophysis. The middle block
was further cut into three sub-blocks. The middle sub-
block (0.1 × 0.1 cm2) was embedded in paraffin. NeuN-
immunolabeling was carried out according to the previous
method [19]. NeuN-immunopositive cells were counted in
three randomly selected fields (400 ×). The number of
NeuN-immunopositive cells was calculated by averaging
the three counts.
Statistical analysis
Neurological deficit scores between groups were analyzed
using a non-parametric test. Quantitative data from the
experiments were expressed as mean ± standard deviation
(S.D.); significance was determined by one-way analysis of
variance (ANOVA) followed by Dunnett's test (SPSS 16.0.
IBM Company,Chicago, USA). In all cases, differences
were considered significant if P <0.05.
Results
Effects of RA on cultured SH-SY5Y cells against oxygen-
glucose deprivation-induced cytotoxicity and apoptosis
As estimated by MTT assay, cell viability was markedly
decreased after OGD for 3 h followed by 12 h incubation
with neurobasal medium (Table 1). However, when cells
were incubated with RA, the cytotoxicity was signifi-
cantly attenuated in a concentration-dependent manner,
as shown in Table 1. To further investigate the protect-
ive effect of RA, LDH leakage rate was estimated, a sig-
nificant increase of LDH leakage rate was observed after
oxygen-glucose deprivation. Incubation with various
concentrations of RA significantly inhibited oxygen-
glucose deprivation-induced LDH release in a concen-
tration-dependent manner.
Apoptotic cells were estimated by flow cytometric ana-
lysis of annexin-V and propidium iodide-labeling cells,
as shown in Figure 1. The normal SH-SY5Y cell apop-
tosis rate was only 3.6 ± 1.5%, after oxygen-glucose
deprivation for 3 h followed by 12 h incubation with
neurobasal medium, the apoptosis of oxygen-glucose
deprivation was increased to 35.8%. Incubation with RA
(3 to 27 μM) for 12 h arrested the apoptosis in a
concentration-dependent manner.
Effects of RA on NF-κB activation and HMGB1 expression
The NF-κB pathway plays a critical role in the secretion
of cytokines. The quantity of p50 and p65 was measured
in the nucleus. Stimulation with TNF-α led to a robust
activation of the NF-κB transcription factor p50/p65.
This activation was partially blocked by RA, as shown in
Figure 2.
The IκB kinase system as another activation agent of
NF-κB was also examined. Stimulation with TNF-α
resulted in a marked degradation of IκB. This degrad-
ation was inhibited by RA (Figure 3). In addition, the
phosphorylation of p-IκB was increased by TNF-
α, and it was also inhibited by RA.
Table 1 Effects of RA on the viability and LDH leakage in
SH-SY5Y cells exposed to oxygen-glucose deprivation
Groups OGD Content (μM) Cell viability (%) LDH leakage (%)
Normal _ — 100.0 ± 4.7 4.1 ± 1.2
Control + — 52.0 ± 6.8# 24.7 ± 4.2#
RA + 1 59.2 ± 7.3 21.9 ± 2.8
+ 3 64.2 ± 5.8* 19.6 ± 3.5*
+ 9 69.0 ± 9.1** 16.5 ± 2.1**
+ 27 72.8 ± 7.4** 14.0 ± 3.1**
+ 81 73.5 ± 8.3** 13.3 ± 1.7**
After 3 h oxygen-glucose deprivation (OGD) followed by 12 h incubation with
RA, cell viability and LDH leakage were assessed. RA indicated Rosmarinic acid.
OGD, oxygen-glucose deprivation. Values are mean ± S.D. (n = 6). Significance
was determined by one-way ANOVA followed by Dunnett's test. #P <0.01
versus normal group; *P <0.05, **P <0.01 versus Control group.
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Phosphor-NF-κB expression was low in SH-SY5Y cells.
However, phosphor-NF-κB expression was significantly
increased after TNF-α 20 ng/ml stimulated SH-SY5Y
cells for 120 minutes. We compared the effect of RA on
the TNF-α-induced activation of phosphor-NF-κB and
HMGB1 expression level in the SH-SY5Y cells to that of
a selective HMGB1 inhibitor, glycyrrhizin. The results of
Figure 3 showed that pretreatment of SH-SY5Y cells
with glycyrrhizin (100 μM) for 120 minutes blocked the
TNF-α-induced HMGB1 expression and reduced phos-
phorylation of NF-κB. Pretreatment of SH-SY5Y cells
with RA 9 μM blocked TNF-α-induced NF-κB phos-







Figure 1 Effects of RA on apoptosis of cultured SH-SY5Y cells. After 3 h oxygen-glucose deprivation (OGD) followed by 12 h incubation with
RA, cell apoptosis was evaluated by flow cytometric analysis. RA indicates rosmarinic acid. Values are mean ± S.D. (n = 6). Significance was
determined by one-way ANOVA followed by Dunnett's test. #P <0.01 vs Control group; *P <0.05, **P <0.01 vs OGD group.
*
*
Figure 2 Effect of RA on TNF-α-induced increase of p50/p65
binding to DNA. SH-SY5Y cells were pre-incubated with RA (9 μM)
for 22 h, then incubated with TNF-α (20 ng/ml) for 2 h. The DNA
binding activity of NF-κB (p50/p65) was determined using an ELISA
kit. RA indicates rosmarinic acid. Results are expressed as fold
increase over control, n = 5. *P <0.01 vs. TNF-α-induced group.
#P <0.01 vs. control group. Significance was determined by one-way
analysis of ANOVA followed by Dunnett’s test.
TNF-α - +     +      +     -
RA - - 9      - 9     















Figure 3 Effects of RA on TNF-α-induced HMGB1 and NF-κB
activation. SH-SY5Y cells were pre-incubated with HMGB1 inhibitor,
glycyrrhizin (100 μM) or RA (9 μM) for 120 minutes and then
incubated with TNF-α (20 ng/ml) for 30 minutes. HMGB1, IκB,
phospho-IκB-α and phospho-NF-κB expression were analyzed by
Western blotting. RA indicates rosmarinic acid. Results are expressed
as fold increase over control, n = 5. *P <0.05, **P <0.01 vs. TNF-α-
induced group. #P <0.01 vs. control group. Significance was
determined by one-way analysis of ANOVA followed by
Dunnett’s test.
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Effects of RA on brain infarct volume, brain water content
and neurological deficit scores in cerebral I/R rats
Cerebral I/R injury leads to severe behavioral disturbance
and histological changes in diabetic MACO rats, ischemic
regions appeared white while non-ischemic region appeared
red. Compared with the diabetic animals, neurological def-
icit scores, the white regions and brain water content were
significantly higher in diabetic cerebral I/R rats.
The results of the dose–response study indicated that
RA at doses of 25, 50, 100 and 200 mg/kg decreased
neurological deficit scores, reduced cerebral infarct vol-
ume and brain water content dose-dependently, did not
reduce blood glucose levels, as shown in Table 2.
The results of the therapeutic time-window study
indicated that RA at a dose of 50 mg/kg decreased
neurological deficit scores, reduced brain infarct volume
and brain water content even with delayed administra-
tion 1 h, 3 h and 5 h after reperfusion. It was obvious
that earlier administration of RA brought more thera-
peutic benefits, as shown in Table 3.
The results of the long-term study indicated that RA at
a dose of 50 mg/kg significantly decreased neurological
deficit scores and reduced cerebral infarction 14 days
after I/R, as shown in Table 4. The results of NeuN
immunolabeling indicated that this is due to a signifi-
cantly increased number of surviving neurons 24 h and
14 days after cerebral I/R, as shown in Figure 4. Thus,
it was clear that early treatment with RA provided
long-term benefits for the neuronal functional recovery
after cerebral I/R.
Effects of RA on cerebral Evans blue extravasation in I/R rats
Evans blue extravasation was used to assess of BBB
breakdown after cerebral ischemia in diabetic rats. Cere-
bral I/R injury led to higher Evans blue extravasation
compared with the diabetic rats. The results clearly
showed that Evans blue extravasation was significantly
attenuated by RA treatment, as shown in Table 5.
Effects of RA on cerebral MPO activity, NF-κB activation
and HMGB1 expression in I/R rats
In order to investigate the molecular mechanism of RA,
cerebral MPO activity, NF-κB activation and HMGB1 ex-
pression were examined. Cerebral MPO activity increased
in rats after cerebral I/R 24 h, but it was very weakly
presented in the diabetic animal, as shown in Table 5. RA
treatment reduced MPO activity in cerebral tissue. Phos-
phorylation of IκB-α and NF-κB both increased in occur-
rence in rats after cerebral I/R, HMGB1 expression also
increased, but they were very weakly presented in the dia-
betic animals, as shown in Figure 5. However, RA treat-
ment not only reduced HMGB1 expression, but also
decreased phosphorylated IκB-α and NF-κB levels. These
data indicated that RA inhibited inflammation response
by reducing MPO activity, blocking NF-κB activation and
HMGB1 expression in diabetic cerebral I/R rats.
Discussion
The present study showed OGD for 3 h followed by
12 h incubation could simulate the brain hypoxia. The
neuronal apoptosis could be activated after treatment
with OGD for 3 h followed by 12 h incubation. The
results showed RA noticeably reduced apoptosis and ne-
crosis, increased cell survival and decreased LDH leak-
age rate in cultured SH-SY5Y) cells. In in vivo study, we
observed RA significantly improved brain injury and did
not reduce blood glucose in diabetic rats subjected to
cerebral I/R challenge; this meant RA has immediate
neuroprotective effect, not by reducing blood glucose.
Infarct size and brain edema are the two important
indicators of the pathophysiology used to evaluate the
efficacy of cerebral ischemia [20]. Our results (Table 2)
revealed that RA treatment produced significant reduc-
tion of cerebral infarct volume and brain water content
in diabetic cerebral I/R rats. Neuronal degeneration and
necrosis have been found to be correlated to deficits in
behavioral disturbance, and behavioral assessment may
Table 2 Effects of RA on ischemia-reperfused diabetic rats: a dose–response study
Group Survival (# rats) Neurological scores
(median/range)
Blood glucose (mM) Infarct volume (%) Brain water
content (%)
Control 10/10 — 5.2 ± 0.6 — 76.8 ± 0.3
Diabetic 10/10 — 19.1 ± 2.3 — 77.0 ± 0.4
Vehicle 8/10 4/2# 19.8 ± 2.5 28.4 ± 5.3# 79.5 ± 0.4#
RA 12.5 9/10 3/3 19.6 ± 2.6 24.5 ± 5.4 79.3 ± 0.4
RA 25 9/10 3/4* 19.5 ± 2.4 21.8 ± 5.7* 79.0 ± 0.5*
RA 50 10/10 2/3** 20.1 ± 2.7 19.7 ± 5.2** 78.9 ± 0.3**
RA 100 10/10 2/3** 19.7 ± 2.6 16.5 ± 4.4** 78.7 ± 0.4**
RA 200 10/10 2/3** 19.6 ± 2.8 15.5 ± 3.2** 78.6 ± 0.5**
Data are means ± SD, with n = 10 for each group. RA at doses ranging from 12.5 to 200 mg/kg, was administered intravenously 30 minutes after cerebral I/R. RA
indicates rosmarinic acid, Control indicates non-diabetic rats. #P <0.01 vs. Diabetic group; *P <0.05, **P <0.01 vs Vehicle-treated group. Cerebral infarct volume and
brain water content between groups were compared using one-way ANOVA followed by Dunnett's test. Neurological scores between groups were compared
using a nonparametric test.
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reveal the effectiveness of a neuroprotective drug [21].
The present study showed that neurological scores were
reduced by treatment with RA (Table 2). NeuN is a sen-
sitive marker for injured neurons early after ischemic
challenge [22]. Our data (Figure 4) demonstrated that RA
50 mg/kg attenuated the decrease of NeuN-immunopositive
neurons in ischemic cerebral cortex 24 h and 14 days after
I/R. This indicated that RA has potentially beneficial effects
in the treatment of cerebral ischemia.
A recent update of the Stroke Therapy Academic In-
dustry Roundtable Preclinical Recommendations [23]
lists three potential reasons for failures in translating ef-
ficacious preclinical findings into successful clinical trial
outcomes; (i) a very tight dose range with a steep dose–
response curve; (ii) inadequate investigation of the thera-
peutic time-window for initiation of treatment and (iii)
differences in the observation period between animal
models and clinical trials. Consequently, we investigated
the dose–response, therapeutic time window and the
long-term efficacy of RA in cerebral I/R rats. Our data
demonstrated that RA exerted potent and long-term
neuroprotective effects with an appropriate dose–re-
sponse curve and a favorable therapeutic time-window
in the model of diabetic cerebral I/R.
Stroke triggers an inflammatory reaction that progresses
for hours after the onset of a stroke, and this inflammation
plays a central role in the pathogenesis of neuronal injury
in ischemic stroke, and especially in diabetic stroke [24].
Inflammatory reactions contribute to the late stages of is-
chemic injury and to worsened neurological outcome
through multiple mechanisms. The present study indicated
that RA had anti-inflammatory effects (Table 5, Figures 3
and 4). Treatment with RA especially provided long-term
benefits for neuronal functional recovery after cerebral I/R
(Table 4). This suggested that the neuroprotective
effects of RA might be due to blocking the inflamma-
tory response.
MPO is considered an index of neutrophil infiltration,
and highly expressed cerebral ischemia after 24 h. It
showed that a significant correlation between neutrophil
infiltration and infarct formation exists in a model of
cerebral ischemia [25]. Our results showed that RA
reduced MPO activity in diabetic ischemic cerebral tissue.
This suggested that the neuroprotective effects of RA
might be due to blocking neutrophil infiltration (Table 5).
BBB permeability is significantly increased in diabetes
due to diabetes-induced damage to the BBB function and/
or due to the immature nature of the newly formed vessel
[26]. BBB breakdown also occur in early phases (within
24 h) of cerebral ischemia [27]. Our data demonstrated
that RA improved diabetic cerebral I/R injury by attenuat-
ing BBB breakdown.
It is well established that NF-κB activation is associated
with the phosphorylation of IκB-α and NF-κB in diabetic
ischemic cerebral tissue. Reduction of NF-κB activation
can protect brain from activation of NF-κB-dependent
genes [28]. Our previous study showed that RA blocked
NF-κB activation in the model of sepsis [11]. HMGB1 is a
novel player in the ischemic brain [29]. Diabetes signifi-
cantly increased serum HMGB level and induced
worse functional outcome after stroke compared to
non-streptozotocin (WT) MCAO rats [30]. Diabetes
exacerbates systemic inflammation as evidenced by
higher serum HMGB1 in the rat systemic inflamma-
tion model [31]. All those indicated HMGB-1 played
a key role in diabetic stroke. HMGB-1 signaling promotes
the chemotaxis and production of cytokines in a process
that involves the activation of NF-κB [32]; inhibitors of NF-
κB kinases alpha and beta are both essential for high mobil-
ity group box 1-mediated chemotaxis [33]. Down-regulation
Table 3 Effects of RA on survival, neurological scores,
infarct volume and brain water content in ischemia-











Diabetic 10/10 — — 77.0 ± 0.5
Vehicle-treated 8/10 4/2 27.7 ± 4.7 79.6 ± 0.4#
1 h 10/10 2/3** 19.0 ± 4.4** 78.8 ± 0.4**
RA 3 h 10/10 2/3* 21.5 ± 4.5** 79.0 ± 0.4*
5 h 9/10 3/4* 22.8 ± 2.8* 79.1 ± 0.4*
7 h 9/10 3/4 24.1 ± 4.0 79.3 ± 0.4
Data are means ± SD, with n = 10 for each group. RA was administered at a
dose of 50 mg/kg at 1 h, 3 h, 5 h and 7 h after cerebral I/R. RA indicates
rosmarinic acid. Data are means ± SD. #P <0.01 vs. diabetic animals; *P <0.05,
**P <0.01 vs vehicle-treated group. Cerebral infarct volumes of different groups
were compared using one-way ANOVA followed by Dunnett's test.
Neurological deficit scores between groups were compared using a
nonparametric test.
Table 4 Effects of RA on survival, neurological scores,
blood glucose and infarct volume in ischemia-reperfused














Vehicle 3 12/15 4/3 20.3 ± 3.1 30.3 ± 5.1
7 12/15 3/4 20.5 ± 3.2
14 12/15 3/4 20.7 ± 3.4
RA50 3 14/15 2/4** 20.5 ± 2.9
7 14/15 2/4* 20.4 ± 3.1
14 14/15 2/4* 20.7 ± 3.2 13.9 ± 4.7**
RA was administered at a dose of 50 mg/kg as a single intravenous bolus
injection 30 minutes after cerebral I/R. RA indicates rosmarinic acid. Data are
means ± SD, each group contains 15 rats. *P <0.05, **P <0.01 vs vehicle-treated
group. Cerebral infarct volumes of different groups were compared using one-
way ANOVA followed by Dunnett's test. Neurological deficit scores between
groups were compared using a nonparametric test.
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of HMGB1 and NF-κB expression protected rat brains
against focal ischemia. Suppression of the release of HMGB1
in astrocytes leads to the attenuation of neuroinflammation,
preventing the necrosis of ischemic astrocytes and NF-κB
expression [34]. HMGB1 recruits various transcription
factors, including NF-κB [35,36]. Inhibition of the up-
regulation of HMGB1 and NF-κB at the early stage brings
great benefits to cerebral ischemia. Based on the above re-
search, we explored the anti-inflammatory properties of RA
in diabetic cerebral ischemia, and further studied the poten-
tial mechanisms. The up-regulation of HMGB1 and NF-κB
were significantly suppressed by RA. These results suggested







Figure 4 Effect of RA on neurological damage 24 h and 14 days in diabetic cerebral ischemia-reperfusion (I/R) rats. A: Effect of RA on
cerebral pathological damage after cerebral I/R in diabetic rats. Sections were stained with NeuN after fixation. A1: diabetic group; A2: Vehicle-
treated group (24 h); A3: RA 50 mg/kg group; A4: Vehicle-treated group (14th day); A5: RA, 50 mg/kg, group (14th day). B: Effect of RA on the
NeuN-immunopositive neurons after cerebral I/R in diabetic rats. RA indicates rosmarinic acid. Results were averaged and expressed as the
number of NeuN-immunopositive neurons per section. Data are means ± SD, n = 5. *P <0.01 vs Vehicle-treated group. Significance was
determined by one-way ANOVA followed by Dunnett’s test.
Table 5 Effect of RA on cerebral Evans blue extravasation
and MPO activity in ischemia-reperfused rats





Control — 0.59 ± 0.13 0.02 ± 0.01
Diabetic — 0.67 ± 0.18 0.03 ± 0.01
Vehicle — 3.93 ± 0.62# 0.18 ± 0.04#
RA 50 1.73 ± 0.42* 0.09 ± 0.02*
Data are means ± SD, with n = 5 for each group. #P <0.01 vs. diabetic animals;
*P <0.01 vs vehicle-treated animals. Significance was determined by one-way










Figure 5 Effects of RA on phosphor-NF-κB, phosphor-IκB-α and
HMGB1 in cerebral I/R rats by western blots analysis 24 h after
I/R. Diabetic rats were subjected to middle cerebral artery occlusion
(MCAO) and reperfusion (I/R) for 23 h. Total protein extracts were
prepared and assayed for phosphor-NF-κB, phosphor-IκB-α and
HMGB1 by Western blot analysis, and blots were normalized to
PCNA expression. RA indicates rosmarinic acid. Results are expressed
as fold increase over sham group, n = 5. *P <0.01 vs. Vehicle-treated
group. #P <0.01 vs. Diabetic group. Significance was determined by
one-way analysis of ANOVA followed by Dunnett’s test.
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participated in the neuroprotection of RA against diabetic
cerebral ischemic damage. Therefore, we believed that the
protective effects of RA might be due to the suppression of
the inflammatory cascades through HMGB1 dependent NF-
κB signaling pathway.
In summary, the results of the current study suggest
that RA exhibit significant neuroprotective effects during
diabetic cerebral I/R injury, including attenuation of
BBB breakdown, a decrease of infarct volume, alleviation
of cerebral damage, reduction of HMGB1 expression,
phosphorylated IκB-α and NF-κB protein expression
in ischemic brain tissue. These effects of RA were cor-
related with inhibition of the inflammatory response.
These findings point to a therapeutic potential for RA as
a useful anti-inflammatory lead compound in early dia-
betic cerebral I/R injury.
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